SEC Form 4 · accession 0001209191-15-028988
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Fractor
Officer — See Remarks
Period of report
Mar 20, 2015
Accepted (ET)
Mar 24, 2015 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 20, 2015 | A | 35,000 | $0.00 | A | 35,000 | D | |
| Common Stock | holding | — | — | — | 41,667 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Rt to Buy)F2 | $0.57 | Mar 20, 2015 | A | 50,000 | A | — | Mar 20, 2025 | Common Stock | 50,000 | 50,000 | D |
| Stock Option (Rt to Buy)F3 | $0.57 | Mar 20, 2015 | A | 50,000 | A | — | Mar 20, 2025 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Reflects the receipt of a restricted stock unit. Each restricted stock unit represents a contingent right to receive one (1) share of Immunocellular Therapeutics, Ltd. common stock. The restricted stock unit shall vest in full on the second anniversary of the grant date.
- F2Option shares shall vest in a series of 48 equal consecutive monthly installments commencing on April 13, 2015 until fully vested.
- F3Option shares shall become fully vested and immediately exercisable if the average daily closing price of Immunocellular Therapeutics, Ltd.'s common stock on the NYSE MKT during any 10 consecutive trading day period exceeds a closing $2.00 weighted average bid and ask price per share (as adjusted for any stock splits and the like).
Remarks
VP, Finance, & Principal Accounting Officer